FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Antibiotic Resistance Market Overview:

According to FutureWise analysis the market for Antibiotic Resistance in 2023 is US$ 8.61 million, and is expected to register a CAGR of 5.90% in 2023-2031

Antibiotics are medications employed in the prevention and treatment of bacterial infections. Antimicrobial resistance appears when microorganisms such as bacteria and fungi develop the capacity to defeat the drugs designed to kill them. It is accelerated by the abuse and overuse of antibiotics and poor infection prevention and management. Resistant infections can be challenging and sometimes impossible to treat. Antibiotic resistance is a naturally occurring process. However, the surge in antimicrobial resistance is driven by a combination of microbes exposed to antibiotics and antifungals and the spread of those microbes with the resistance mechanisms. These mechanisms can result in bacteria surviving the effects of specific antibiotics and developing a resistance that can be passed to other bacteria during reproduction. In addition, bacteria can become resistant through mutation of their genetic material.

Antibiotic resistance is classified into different types, including complicated urinary tract infections (cuti), bloodstream infections (CDI), complicated intra-abdominal infections (ciai), and clostridium difficile infections (CDI). Complicated urinary tract infections (cUTI) occur in individuals with functional, structural, or metabolic abnormalities of the genitourinary tract, such as obstruction, neurological impairment, urological abnormalities/devices, immunological impairment, and congenital diseases. These infections are caused frequently by multidrug-resistant Gram-negative bacilli. The most significant risk is that untreated or resistant infections can lead to kidney problems (like pyelonephritis) or even more serious conditions like sepsis (or urosepsis). However, it is also very difficult to live with the ongoing signs of recurring or antibiotic resistant UTIs.

FutureWise Market Research has published a report that provides an insightful analysis antibiotic resistance market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, antibiotic resistance market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

Major players included in the Antibiotic Resistance Market:

Achaogen, Inc.
Basilea Pharmaceutica Ltd.
Melinta Therapeutics
Tetraphase Pharmaceuticals, Inc.
Theravance Biopharma, Inc.
Wockhardt therapeutics
Entasis Therapeutics
Paratek therapeutics
Seres Therapeutics, Inc.
Pfizer
Merck
Allergan
Pall Corporation
Cytiva
Bio-Rad Laboratories

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Antibiotic Resistance Market:

In June 2023, BSI, the business improvement and standards company, launched a new global Minimized Risk of Antimicrobial Resistance (AMR) certification developed to promote and attest to the responsible manufacturing of antibiotics in the global supply chain.
In November 2022, Quadripartite launched a new platform to tackle antimicrobial resistance threats to human and animal health and ecosystems. The Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched to ensure the increasing threats and consequences of antimicrobial resistance.

The increasing prevalence of antibiotic-resistant infections caused by bacteria such as Clostridium difficile, Staphylococcus aureus, E. coli, and Pseudomonas aeruginosa significantly propelled the growth of the antibiotic resistance market. These pathogens have developed resistance against conventional antibiotics, increasingly causing ineffective standard therapies. For example, E. coli, has developed into strains resistant to multiple drug types, posing significant barriers in clinical settings. Similarly, the prevalence of resistant strains of Pseudomonas and Staphylococcus aureus, including MRSA, further emphasizes the critical need for cutting-edge therapeutic options. Moreover, the abuse and overuse of antibiotics, prevalent in both healthcare and agriculture, are likely to drive the antibiotic resistance market. This disturbing tendency requires the development of novel and highly effective antibiotics. In healthcare, improper prescription practices and patient non-compliance contribute to the resistance, while in agriculture, the widespread usage of antibiotics in livestock farming worsens the problem. Therefore, these practices demand innovative antibiotics and further ensure the effectiveness of medical interventions for infectious diseases. However, non-antibiotic treatments like phage therapy and immunotherapies present a potential constraint for the antibiotic resistance market. While promising, these innovative approaches face hurdles in regulatory approval and clinical practices. Phage therapy, for example, involves the use of bacteriophages, which are viruses that contaminate and kill bacteria. Conversely, immunotherapies require an in-depth knowledge of the host immune response and may not be effective against all bacterial infections. Therefore, impeding the growth of the antibiotic resistance market over the forecast period.

Antibiotic Resistance Market Segmentation:

By Disease

Complicated Urinary Tract Infection (cUTI)
Complicated Intra-Abdominal Infections (cIAI)
Blood Stream Infections (BSI)
Clostridium difficile infections (CDI)
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)

By Pathogen

Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
Pseudomonas aeruginosa (Carbapenem-Resistant)
Staphylococcus Aureus (Methicillin-Resistant)
E.coli/K. pneumoniae (Carbapenem-Resistant)
Streptococcus pneumoniae (Penicillin-Non-Susceptible)
Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
Enterococcus faecium (Vancomycin-Resistant)
Haemophilus Influenzae (Ampicillin-Resistant)

By Drug Class

Oxazolidinones
Lipoglycopeptides
Tetracyclines
Cephalosporins
Combination therapies
Others

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to the high burden of antibiotic-resistant Gram-negative infections, recent launches to address drug resistance, increasing research and development activities related to antibiotics, and growing investment in healthcare infrastructure are boosting the market's growth. For instance, in January 2023, Alkem Laboratories launched an antibiotic, Zidavi, for multiple drug-resistant (MDR) infections. Moreover, government initiatives and compulsory insurance policies in the region are expected to drive the growth of the antibiotic resistant market over the forecast period.

Competitive Landscape:

Tier 1 players- established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the Antibiotic Resistance Market By Disease, By Pathogen, By Drug Class and By Region.
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
To record and evaluate competitive landscape mapping- Targeted Antigen launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1 . Years Considered for the Study
  3.2 . Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1 . Secondary Data
  1.1.1 . Key Data from Secondary Sources
  1.2 . Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Antibiotic Resistance Market Variables, Trends and Scope
- 1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Technology Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Antibiotic Resistance Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Antibiotic Resistance Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Technology Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Technology Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Antibiotic Resistance Market, By Disease Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Complicated Urinary Tract Infection (cUTI)
  2. Complicated Intra-Abdominal Infections (cIAI)
  3. Blood Stream Infections (BSI)
  4. Clostridium difficile infections (CDI)
  5. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  6. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  7. Community Acquired Bacterial Pneumonia (CABP)
8. Antibiotic Resistance Market, By Pathogen Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
  2. Pseudomonas aeruginosa (Carbapenem-Resistant)
  3. Staphylococcus Aureus (Methicillin-Resistant)
  4. E.coli/K. pneumoniae (Carbapenem-Resistant)
  5. Streptococcus pneumoniae (Penicillin-Non-Susceptible)
  6. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
  7. Enterococcus faecium (Vancomycin-Resistant)
  8. Haemophilus Influenzae (Ampicillin-Resistant)
9. Antibiotic Resistance Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Oxazolidinones
  2. Lipoglycopeptides
  3. Tetracyclines
  4. Cephalosporins
  5. Combination therapies
  6. Others
10. North America Antibiotic Resistance Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2023-2031
11. Latin America Antibiotic Resistance Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2023-2031
12. Europe Antibiotic Resistance Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2023-2031
13. Asia Pacific Antibiotic Resistance Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031
14. Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. GCC
  2.2. Israel
  2.3. South Africa
  2.4. Rest of MEA
  3. Market Size (USD Million) Forecast for MEA 2023-2031
15. Market Share Analysis and Competitive Landscape
- 1. Global Landscape - Key Players, Revenue and Presence
  2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
  3. Global Emerging Companies
  4. North America - Market Share Analysis and Key Regional Players
  5. Europe - Market Share Analysis and Key Regional Players
  6. Asia Pacific - Market Share Analysis and Key Regional Players
  7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Targeted Antigens Offered and Financial Layouts)
- 1. Achaogen, Inc.
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Basilea Pharmaceutica Ltd.
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. Melinta Therapeutics
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. Tetraphase Pharmaceuticals, Inc.
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. Theravance Biopharma, Inc.
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. Wockhardt therapeutics
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. Entasis Therapeutics
  7.1. Company Overview
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Paratek therapeutics
  8.1. Company Overview
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
  9. Seres Therapeutics, Inc.
  9.1. Company Overview
  9.2. Product Portfolio
  9.3. SWOT Analysis
  9.4. Financial Overview
  9.5. Strategic Overview
  10. Pfizer
  10.1. Company Overview
  10.2. Product Portfolio
  10.3. SWOT Analysis
  10.4. Financial Overview
  10.5. Strategic Overview
  11. Merck
  11.1. Company Overview
  11.2. Product Portfolio
  11.3. SWOT Analysis
  11.4. Financial Overview
  11.5. Strategic Overview
  12.Allergan
  12.1. Company Overview
  12.2. Product Portfolio
  12.3. SWOT Analysis
  12.4. Financial Overview
  12.5. Strategic Overview
  13. Pall Corporation
  13.1. Company Overview
  13.2. Product Portfolio
  13.3. SWOT Analysis
  13.4. Financial Overview
  13.5. Strategic Overview
  14. Cytiva
  14.1. Company Overview
  14.2. Product Portfolio
  14.3. SWOT Analysis
  14.4. Financial Overview
  14.5. Strategic Overview
  15. Bio-Rad Laboratories
  15.1. Company Overview
  15.2. Product Portfolio
  15.3. SWOT Analysis
  15.4. Financial Overview
  15.5. Strategic Overview
17. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by administrations
  5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients